Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

Core Insights - Eledon Pharmaceuticals has received Orphan Drug designation from the FDA for tegoprubart, aimed at preventing allograft rejection in liver transplantation [1][2] - Tegoprubart has previously been designated for pancreatic islet cell transplantation and for treating amyotrophic lateral sclerosis (ALS) [1] - The company is optimistic about the potential of tegoprubart in liver transplantation, supported by preclinical evidence and plans for an investigator-sponsored trial later this year [2] Company Overview - Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [3] - The lead product, tegoprubart, is an anti-CD40L antibody with high affinity for the CD40 Ligand, which is a significant target for immunomodulatory therapies [3] - The company is conducting studies in various transplantation settings, including kidney, xenotransplantation, islet cell, liver transplantation, and ALS [3]